Imfinzi puts its flag on the Matterhorn
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
Hello BridgeBio, farewell Syros and Achilles
One step forward, two steps back for biotech.
FDA red and green lights: February 2025
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
The month ahead: March's upcoming events
Another SERD catalyst and the son of Darzalex take centre stage.
Regeneron shoots again with odronextamab
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
Boehringer beats Bayer to the regulators
The FDA will rule on a low dose of zongertinib in the summer.
Chimerix's cancer transformation
US approval could mark the company's graduation to oncology.
